Welcome to our dedicated page for Oculis Holding Ordinary shares news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding Ordinary shares stock.
Oculis Holding AG (Nasdaq: OCS) is a leading global biopharmaceutical company dedicated to saving sight and enhancing eye care. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is at the forefront of developing innovative treatments for serious eye diseases. The company's pipeline includes several promising candidates:
- OCS-01: A topical eye drop for diabetic macular edema (DME) and post-cataract surgery inflammation and pain. OCS-01 has shown compelling Phase 3 data, making it a potential new standard of care for these conditions.
- OCS-02: A topical biologic anti-TNFα eye drop for dry eye disease (DED) and non-infectious anterior uveitis. The OCS-02 RELIEF trial is in Phase 2b, with results eagerly anticipated.
- OCS-05: A neuroprotective candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma and diabetic retinopathy. The ACUITY trial is set to provide critical data by the end of the year.
Oculis recently announced its fourth-quarter and full-year 2023 financial results, highlighted by positive Phase 3 data for OCS-01 and the commencement of three clinical trials, including OCS-02's RELIEF trial. The company is on track for a catalyst-rich 2024 with significant upcoming milestones, including readouts from the RELIEF trial in Q2 and the OPTIMIZE-2 and ACUITY trials in Q4. These milestones are crucial for Oculis' plan to submit its first New Drug Application (NDA).
Under the leadership of CEO Riad Sherif, M.D., Oculis has achieved remarkable progress and continues to advance its diversified pipeline. The company is backed by leading international healthcare investors and boasts a seasoned management team with a strong track record of success.
Financially, Oculis has reported significant strides, supported by both new and existing investors. The company has dual listings on Nasdaq in the U.S. and Iceland, reflecting its robust financial health and market confidence.
For more information, please visit Oculis Holding AG's website. For investor and media inquiries, contact Ms. Sylvia Cheung, CFO at sylvia.cheung@oculis.com or Corey Davis, Ph.D. at LifeSci Advisors at cdavis@lifesciadvisors.com.
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) reports a successful year with positive Phase 3 results in OCS-01 for Diabetic Macular Edema and inflammation following cataract surgery. The company plans to release data from OCS-02 Phase 2b RELIEF trial in Dry Eye Disease in Q2 2024 and OCS-01 Phase 3 OPTIMIZE-2 trial in Q4 2024. Financially, Oculis has $108.9 million in cash and short-term investments, with a focus on advancing key programs and clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) provides updates on its late-stage clinical trials and management appointments. The company completed enrollment in the Phase 2b RELIEF trial of OCS-02 for Dry Eye Disease, initiated the DIAMOND-2 Phase 3 trial for Diabetic Macular Edema, and made key executive appointments. Topline results for the RELIEF trial are expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced its participation in upcoming investor conferences, including the Stifel Biotech Executive Summit and BioCapital Europe 2024. The company's CEO and CFO will be presenting at these events, providing an opportunity for interested investors to engage with Oculis' management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced an in-person R&D Day in New York City to showcase two clinical programs: OCS-01, a high concentration dexamethasone eye drop formulation for Diabetic Macular Edema, and OCS-02, a TNFα inhibitor licaminlimab eye drop formulation for Dry Eye Disease. The event will feature presentations from renowned medical professionals and provide a 2023 review and business outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced the initiation of the second Phase 3 OPTIMIZE-2 trial with OCS-01, a once-daily eye drop for the treatment of inflammation and pain following cataract surgery. The trial aims to support the NDA submission to the FDA, with the topline readout expected before the end of 2024. OCS-01 is also being evaluated for the treatment of Diabetic Macular Edema (DME) and Cystoid Macular Edema (CME) in separate trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announces the initiation of the DIAMOND-1 Phase 3 trial to evaluate the efficacy and safety of OCS-01 eye drops in treating Diabetic Macular Edema (DME) patients. Stage 1 results demonstrated the superiority of OCS-01 over the vehicle, with robust statistical significance and no unexpected adverse events. OCS-01 has the potential to become the first topical eye drop and non-invasive treatment option for DME. The second 52-week Phase 3 trial, DIAMOND-2, is anticipated to start in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announces the initiation of the Phase 2b RELIEF trial to evaluate the potential of licaminlimab (also known as OCS-02), a novel anti-TNFα biologic eye drop, for the treatment of Dry Eye Disease (DED). The trial aims to assess the efficacy and safety of licaminlimab in moderate-to-severe DED, with topline results expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) reported that its lead product candidate OCS-01 eye drop met primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery, following a positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME). The company also enrolled the first patient in the investigator-initiated LEOPARD trial evaluating OCS-01 for the treatment of cystoid macular edema (CME). Oculis has cash and investments of $116.5 million, which is adequately funded to deliver on key business and clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced that its CEO and CFO will be presenting at upcoming investor conferences, including the Stifel 2023 Healthcare Conference and BTIG 3rd Annual Ophthalmology Day. The management team will also attend the Piper Sandler 35th Annual Healthcare Conference, offering one-on-one meetings for interested investors. Links to access company presentation and webcast for select events will be posted to Oculis’ website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
Rhea-AI Summary
Oculis Holding AG announced positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME). The results will be presented at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting. OCS-01 is the first investigational eye drop for both front and back of the eye indications, with positive results in previous trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
FAQ
What is the current stock price of Oculis Holding Ordinary shares (OCS)?
The current stock price of Oculis Holding Ordinary shares (OCS) is $14.75 as of November 21, 2024.
What is the market cap of Oculis Holding Ordinary shares (OCS)?
The market cap of Oculis Holding Ordinary shares (OCS) is approximately 616.2M.
What is Oculis Holding AG?
Oculis Holding AG is a global biopharmaceutical company focused on developing treatments for serious eye diseases, including diabetic macular edema and dry eye disease.
What products are in Oculis' pipeline?
Oculis' pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and other neuro-ophthalmic disorders.
Where is Oculis headquartered?
Oculis is headquartered in Switzerland, with additional operations in the U.S. and Iceland.
What recent achievements has Oculis made?
In 2023, Oculis had positive Phase 3 results for OCS-01 and initiated three clinical trials, including the OCS-02 Phase 2b RELIEF trial for dry eye disease.
Who leads Oculis Holding AG?
Oculis is led by CEO Riad Sherif, M.D., alongside an experienced management team with a successful track record and support from leading international healthcare investors.
What are the upcoming milestones for Oculis in 2024?
Upcoming milestones include the RELIEF trial readout for OCS-02 in Q2, and Phase 3 readouts for OCS-01 and OCS-05 in Q4, along with the submission of the first NDA.
How did Oculis perform financially in 2023?
Oculis reported strong financial results for 2023, supported by significant investor backing and a successful dual listing on Nasdaq in the U.S. and Iceland.
What conditions does OCS-01 treat?
OCS-01 is a topical eye drop candidate for treating diabetic macular edema (DME) and for post-cataract surgery inflammation and pain.
What is the OCS-02 RELIEF trial?
The OCS-02 RELIEF trial is a Phase 2b clinical study evaluating the efficacy of OCS-02, a topical biologic anti-TNFα eye drop, for treating dry eye disease (DED).
How can I contact Oculis for investor or media inquiries?
For inquiries, you can contact CFO Sylvia Cheung at sylvia.cheung@oculis.com or Corey Davis, Ph.D., at cdavis@lifesciadvisors.com.
Oculis Holding AG Ordinary shares